In Vitro Performance of the Wixela Inhub Inhaler Using Severe Chronic Obstructive Pulmonary Disease Patient Inhalation Profiles.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of aerosol medicine and pulmonary drug delivery"
DOI: 10.1089/jamp.2021.0017
Abstract: Background: Wixela Inhub (trademarks of Viatris, Inc.) is a dry powder inhaler (DPI) that delivers a fixed-dose combination of fluticasone propionate and salmeterol and is approved as a generic equivalent to Advair Diskus (trademarks of… read more here.
Keywords: inhaler; fluticasone propionate; wixela inhub; inhalation profiles ... See more keywords